Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours.
Yong-Il KimChanghoon YooSeung Jun OhSang Ju LeeJunho KangHee-Sang HwangSeung-Mo HongBaek-Yeol RyooJin-Sook RyuPublished in: EJNMMI research (2020)
Low TLR, determined via [68Ga]Ga-DOTA-TOC PET/CT, can be a factor of worse prognosis in patients with advanced WD GEP-NETs treated with lanreotide.